Jonathan Francois
Cardiovascular Disease · Atlantis, FLNPI 1922505866
Payments from drug & device makers
Across 380 payments — averaging $118.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$14K
- Abbott$13K
- Biotronik Inc.$6K
- Boston Scientific$6K
- Biosense Webster, Inc.$4K
- Philips North America LLC$972
- plus $302 from 7 others
What the payments were for
- Travel & lodging$25,81157%
- Food & beverage$18,14740%
- Education$9522%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 114 | $14,448 |
| Abbott | 107 | $12,954 |
| Biotronik Inc. | 32 | $6,227 |
| Boston Scientific | 42 | $6,059 |
| Biosense Webster, Inc. | 67 | $3,950 |
| Philips North America LLC | 10 | $972 |
| Medical Device Business Services, Inc. | 1 | $100 |
| Irhythm Technologies, Inc. | 1 | $87 |
| Pfizer | 2 | $54 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| Merck | 1 | $20 |
| AstraZeneca | 1 | $13 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENSITE$3,830
- ENSITE PRECISION$2,877
- GALLANT$2,254
- VersaCross Access Solution$2,110
- Carto 3$2,038
- Micra$1,078
- WATCHMAN Access System$809
- Rivacor 7 DR-T$670
- Acticor 7 VR-T DX$670
- Edora 8 DR-T$670
- Solia$466
- BioMonitor$466
- (9124) LM Undivided$309
- (9520) IGT Devices Undivided$272
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$260
- AVEIR$240
- Sentus$204
- AURORA EV-ICD MRI SURESCAN$162
- CARDIOMEMS$146
- CARDIOBLATE CRYOFLEX$120
How this compares
$44,910 in reported general payments places this provider in the 85th percentile of 1,740 cardiovascular disease providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 12 | $12,477 |
| Metoprolol Succinate | 15 | $184 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $13 | $12,47712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Atlantis
- Michael KorenGainesville$31M
- Seth BaumBoca Raton$11.1M
- Alexis GutierrezHialeah$8M
- Eric SpivackAventura$7.1M
- William OneillNaples$4.6M
- Rafik AbadierInverness$4.4M
- Alvaro MurciaPembroke Pines$4M
- David HotchkissPort Charlotte$4M
- Ferris GeorgeSt Augustine$3.8M
- Duccio BaldariWellington$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.